Protein C News and Research

RSS

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology.

7 Oct 2010

Laureate Pharma secures $20 million financing to enhance business

Laureate Pharma, Inc., a full-service contract development and manufacturing organization today announced that it has secured $20 million in debt and equity financing to enhance and grow its business.

7 Oct 2010

Immune reaction to dystrophin may contribute to muscle disease: Study

An immune reaction to dystrophin, the muscle protein that is defective in patients with Duchenne muscular dystrophy, may pose a new challenge to strengthening muscles of patients with this disease, suggests a new study appearing in the October 7, 2010, issue of The New England Journal of Medicine.

7 Oct 2010

Research findings likely to have significant implications for treatment of pre-eclampsia, hypertension

Scientists have discovered a mechanism which raises blood pressure in pre-eclampsia, a potentially deadly condition which occurs during pregnancy.

7 Oct 2010

Microglial inflammation promotes MAPT pathologies

Cells that help to protect the central nervous system may also contribute to pathological changes in the brain. New research, published by Cell Press in the October 7th issue of the journal Neuron, provides mechanistic insight into a link between the immune system and neurodegenerative disorders like Alzheimer's disease that are associated with abnormal accumulation of tau protein.

7 Oct 2010

Patients with muscular dystrophy mount immune response to dystophin protein prior to gene therapy: Study

A clinical trial designed to replace the genetic defect causing the most common form of muscular dystrophy has uncovered an unexpected aspect of the disease. The trial, based on therapy designed by scientists at the University of North Carolina at Chapel Hill School of Medicine, showed that some patients mount an immune response to the dystrophin protein even before they have received the gene therapy.

7 Oct 2010

New hope for patients with brain injury

New neuroscience research by life scientists from UCLA and Australia may potentially help people who have lost their ability to remember due to brain injury or disease.

6 Oct 2010

Study may lend insight about hallucination mechanism in schizophrenia

Scripps Research Institute scientists have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway to mediate biological functions that are distinct from the signaling pathways used by hallucinogenic substances. The new findings could have a profound effect on the development of new therapies for a number of disorders, including schizophrenia and depression.

6 Oct 2010

Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement

ACR Image Metrix, a global imaging contract research organization (CRO) with expertise in imaging trial design, techniques and data extraction, is pleased to announce a Phase III trial, conducted for Aegerion Pharmaceuticals, Inc., was published as an abstract in the online supplement of Atherosclerosis and presented at the 78th European Atherosclerosis Society Congress, which took place June 20-23, 2010, in Hamburg, Germany.

6 Oct 2010

Toxic free radical responsible for lung damage due to oxygen therapy

The most toxic free radical appears responsible for much of the lung damage that can result from oxygen therapy in the critically ill or injured, Medical College of Georgia researchers report.

6 Oct 2010

Insulin-sensitizing drugs may offer new treatments for kidney failure

Evidence reported in the October issue of Cell Metabolism, a Cell Press publication, offers a completely new explanation for why people with diabetes account for more than half of all patients requiring dialysis or kidney transplantation. It appears that insulin has a significant influence on the structure and proper function of a particular group of very specialized cells, known as podocytes, that are integral to the kidney's ability to do its job filtering blood.

6 Oct 2010

Low level of testosterone increases risk for Alzheimer's disease

Low levels of the male sex hormone, testosterone, in older men is associated with the onset of Alzheimer's disease, according to research by a team that includes a Saint Louis University scientist.

6 Oct 2010

Profectus BioSciences awarded $3.1M Fast Track SBIR grant to develop prophylactic vaccine against HIV

Profectus BioSciences, Inc., a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases, today announced the award of a Fast Track SBIR from the Division of AIDS, National Institutes of Health for $3.1M to support the development of the Company's Transition State Vaccine (TSV) technology for a prophylactic HIV Vaccine.

6 Oct 2010

Knome announces winners of KnomeDISCOVERY Awards

Knome, Inc. today announced the winners of its inaugural KnomeDISCOVERY Awards, a program designed to spur new genetic insights into health.

6 Oct 2010

Isogenica, NovaBiotics to accelerate the development of peptide anti-infective technology

Isogenica Ltd, today announced that it has entered into a collaboration agreement with NovaBiotics, a leading clinical-stage biotechnology company to fast-track the development of NovaBiotic's platform peptide anti-infective technology.

6 Oct 2010

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

Intellect Neurosciences, Inc., a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a patent from the United States Patent and Trademark Office (USPTO) related to its internal Alzheimer's disease (AD) monoclonal antibody program.

5 Oct 2010

International experts to discuss effect of diet on children's mental and behavioral development

Can diet affect our children's long-term mental and behavioural development. This question will be addressed by a number of international leading experts on child nutrition next 6th of October in York, at a public event organized within the 7th Framework Programme Nutrimenthe, entitled "Effect of diet on the mental performance of children".

5 Oct 2010

RHUCIN clinical trial results published in JACI journal

Santarus, Inc., a specialty biopharmaceutical company, today announced the publication of an integrated analysis of two randomized placebo-controlled clinical trials with RHUCIN (recombinant human C1 inhibitor, or rhC1INH), in the October issue of the peer reviewed Journal of Allergy and Clinical Immunology (JACI).

5 Oct 2010

Researchers reveal ways to halt Rett Syndrome

In a study published today in the Journal, Proceedings of the National Academy of Sciences, an international team of researchers based in the U.S. and UK revealed that they were able to halt the potentially lethal, breath holding episodes associated with the neurological disease Rett syndrome.

5 Oct 2010

Tasly, ProteoTech to co-develop Exebryl-1(R) medication for Alzheimer's disease treatment

Tasly Pharmaceutical Co., Ltd. and ProteoTech, Inc. today announced an agreement to co-develop ProteoTech's novel small molecule therapeutic, Exebryl-1(R), for the treatment of mild-to-moderate Alzheimer's disease.

5 Oct 2010

Protein C News and Research

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

Laureate Pharma secures $20 million financing to enhance business

Immune reaction to dystrophin may contribute to muscle disease: Study

Research findings likely to have significant implications for treatment of pre-eclampsia, hypertension

Microglial inflammation promotes MAPT pathologies

Patients with muscular dystrophy mount immune response to dystophin protein prior to gene therapy: Study

New hope for patients with brain injury

Study may lend insight about hallucination mechanism in schizophrenia

Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement

Toxic free radical responsible for lung damage due to oxygen therapy

Insulin-sensitizing drugs may offer new treatments for kidney failure

Low level of testosterone increases risk for Alzheimer's disease

Profectus BioSciences awarded $3.1M Fast Track SBIR grant to develop prophylactic vaccine against HIV

Knome announces winners of KnomeDISCOVERY Awards

Isogenica, NovaBiotics to accelerate the development of peptide anti-infective technology

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

International experts to discuss effect of diet on children's mental and behavioral development

RHUCIN clinical trial results published in JACI journal

Researchers reveal ways to halt Rett Syndrome

Tasly, ProteoTech to co-develop Exebryl-1(R) medication for Alzheimer's disease treatment

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News